Marisa Wexler, MS, senior science writer —

An algorithm can accurately identify people who are at increased risk of developing Parkinson’s-like motor problems in coming years, a new study shows. The study, “The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson’s Disease,” was published in Movement Disorders. The…

Coya Therapeutics has secured an exclusive license to patent rights and know-how related to the company’s experimental anti-inflammatory therapy COYA 301, alone or in combination with other molecules, for Parkinson’s disease. The license was part of an agreement with UNeMed, the technology transfer office of the University…

People with Parkinson’s who smoke cigarettes or use aspirin tend to report more problems with certain disease symptoms, according to a new study. The study, however, did not find notable associations between drinking coffee and Parkinson’s symptom severity. “This study comprehensively assesses the effect of smoking, coffee drinking, and aspirin…

Programs focusing on traditional forms of Brazilian dance may help to improve life quality and ease motor symptoms for people with Parkinson’s disease, a new study reports. “The findings of this study suggest that Brazilian dance practice is capable of improving the perception of some aspects of quality of life…

Researchers have created a novel formulation of pramipexole — the active agent in Mirapex — that can be administered via a film placed on the inside of the cheek. The new formulation may make treatment easier for people with Parkinson’s disease who have trouble swallowing, scientists said in…

A new device, worn like a wristwatch to help control tremor in people with Parkinson’s disease, is now available in the U.S. from its developer, Cala Health. Called the Cala kIQ System, the wearable device is the first to be cleared by the U.S. Food and Drug Administration…

Combining a singing program with conventional speech therapy could help to lessen the vocal problems facing people with Parkinson’s disease, according to findings from a small clinical trial. Therapy sessions were conducted using smartphones, and given to patients at the home. The study, “Voice improvement following…

Kynmobi (apomorphine hydrochloride), an under-the-tongue therapy approved to help manage off episodes in Parkinson’s disease, is being discontinued in the U.S. as of June 30. Sunovion, which developed the treatment, is voluntarily withdrawing the drug from the U.S. market “due to limited utilization,” according to an announcement…

Use of certain anti-depressants may increase the risk of life-threatening clotting problems in elderly people with Parkinson’s disease, a new report highlights. The study, “Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson’s disease: a case report,” was published in BMC…

The Phase 2 LUMA clinical trial, which is testing the experimental LRRK2 inhibitor BIIB122 in people with Parkinson’s disease, is expanding to open enrollment of patients who have a mutation in the LRRK2 gene, in addition to patients without mutations. Meanwhile, the Phase 3 LIGHTHOUSE study, which had been…